Literature DB >> 23622939

Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies.

Wilhelmina G Melsen1, Maroeska M Rovers, Rolf H H Groenwold, Dennis C J J Bergmans, Christophe Camus, Torsten T Bauer, Ernst W Hanisch, Bengt Klarin, Mirelle Koeman, Wolfgang A Krueger, Jean-Claude Lacherade, Leonardo Lorente, Ziad A Memish, Lee E Morrow, Giuseppe Nardi, Christianne A van Nieuwenhoven, Grant E O'Keefe, George Nakos, Frank A Scannapieco, Philippe Seguin, Thomas Staudinger, Arzu Topeli, Miquel Ferrer, Marc J M Bonten.   

Abstract

BACKGROUND: Estimating attributable mortality of ventilator-associated pneumonia has been hampered by confounding factors, small sample sizes, and the difficulty of doing relevant subgroup analyses. We estimated the attributable mortality using the individual original patient data of published randomised trials of ventilator-associated pneumonia prevention.
METHODS: We identified relevant studies through systematic review. We analysed individual patient data in a one-stage meta-analytical approach (in which we defined attributable mortality as the ratio between the relative risk reductions [RRR] of mortality and ventilator-associated pneumonia) and in competing risk analyses. Predefined subgroups included surgical, trauma, and medical patients, and patients with different categories of severity of illness scores.
FINDINGS: Individual patient data were available for 6284 patients from 24 trials. The overall attributable mortality was 13%, with higher mortality rates in surgical patients and patients with mid-range severity scores at admission (ie, acute physiology and chronic health evaluation score [APACHE] 20-29 and simplified acute physiology score [SAPS 2] 35-58). Attributable mortality was close to zero in trauma, medical patients, and patients with low or high severity of illness scores. Competing risk analyses could be done for 5162 patients from 19 studies, and the overall daily hazard for intensive care unit (ICU) mortality after ventilator-associated pneumonia was 1·13 (95% CI 0·98-1·31). The overall daily risk of discharge after ventilator-associated pneumonia was 0·74 (0·68-0·80), leading to an overall cumulative risk for dying in the ICU of 2·20 (1·91-2·54). Highest cumulative risks for dying from ventilator-associated pneumonia were noted for surgical patients (2·97, 95% CI 2·24-3·94) and patients with mid-range severity scores at admission (ie, cumulative risks of 2·49 [1·81-3·44] for patients with APACHE scores of 20-29 and 2·72 [1·95-3·78] for those with SAPS 2 scores of 35-58).
INTERPRETATION: The overall attributable mortality of ventilator-associated pneumonia is 13%, with higher rates for surgical patients and patients with a mid-range severity score at admission. Attributable mortality is mainly caused by prolonged exposure to the risk of dying due to increased length of ICU stay. FUNDING: None.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23622939     DOI: 10.1016/S1473-3099(13)70081-1

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  204 in total

1.  Prone position acute respiratory distress syndrome patients: less prone to ventilator associated pneumonia?

Authors:  H Dupont; P Depuydt; F Abroug
Journal:  Intensive Care Med       Date:  2016-01-14       Impact factor: 17.440

2.  Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.

Authors:  J C Bader; E A Lakota; G E Dale; H S Sader; J H Rex; P G Ambrose; S M Bhavnani
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 3.  Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection.

Authors:  Colleen S Curran; Thomas Bolig; Parizad Torabi-Parizi
Journal:  Am J Respir Crit Care Med       Date:  2018-03-15       Impact factor: 21.405

4.  A 2015 Update on Ventilator-Associated Pneumonia: New Insights on Its Prevention, Diagnosis, and Treatment.

Authors:  Braden Waters; John Muscedere
Journal:  Curr Infect Dis Rep       Date:  2015-08       Impact factor: 3.725

5.  Performance of the extended use of the FilmArray® BCID panel kit for bronchoalveolar lavage analysis.

Authors:  Maxime Sansot; Eugénie Fradin; Rachel Chenouard; Marie Kempf; Achille Kouatchet; Sigismond Lasocki; Carole Lemarié; Matthieu Eveillard; Hélène Pailhoriès
Journal:  Mol Biol Rep       Date:  2019-02-23       Impact factor: 2.316

6.  Is prophylaxis worse than treatment in the ICU?

Authors:  Fernando G Zampieri; Matt P G Morgan; Morten Hylander Møller
Journal:  Intensive Care Med       Date:  2019-07-29       Impact factor: 17.440

7.  Colonization pressure as a risk factor of ICU-acquired multidrug resistant bacteria: a prospective observational study.

Authors:  J Masse; A Elkalioubie; C Blazejewski; G Ledoux; F Wallet; J Poissy; S Preau; S Nseir
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-12-20       Impact factor: 3.267

8.  Healthcare-associated pneumonia among U.S. combat casualties, 2009 to 2010.

Authors:  Heather C Yun; Amy C Weintrob; Nicholas G Conger; Ping Li; Dan Lu; David R Tribble; Clinton K Murray
Journal:  Mil Med       Date:  2015-01       Impact factor: 1.437

Review 9.  [Nosocomial pneumonia from a radiological perspective].

Authors:  P Agarwal; A Wielandner
Journal:  Radiologe       Date:  2017-01       Impact factor: 0.635

10.  Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution.

Authors:  Sujata M Bhavnani; Jeffrey P Hammel; Elizabeth A Lakota; M Courtney Safir; Brian D VanScoy; Yu Nagira; Christopher M Rubino; Nobuo Sato; Tomokazu Koresawa; Kenichiro Kondo; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.